Becton Dickinson and (BDX) Given “Buy” Rating at Bank of America

Becton Dickinson and (NYSE:BDX)‘s stock had its “buy” rating restated by stock analysts at Bank of America in a research report issued on Friday, January 19th, Marketbeat reports. They currently have a $260.00 price objective on the medical instruments supplier’s stock. Bank of America’s price target would suggest a potential upside of 18.21% from the company’s previous close.

BDX has been the topic of several other research reports. Royal Bank of Canada reissued a “hold” rating and issued a $210.00 target price on shares of Becton Dickinson and in a report on Wednesday, October 25th. Zacks Investment Research raised shares of Becton Dickinson and from a “hold” rating to a “buy” rating and set a $234.00 target price on the stock in a report on Tuesday, October 31st. Citigroup upgraded shares of Becton Dickinson and from a “sell” rating to a “neutral” rating in a research report on Friday, January 5th. Wells Fargo & Co began coverage on shares of Becton Dickinson and in a research report on Friday, September 22nd. They issued an “outperform” rating and a $225.00 price target on the stock. Finally, Stifel Nicolaus restated a “buy” rating and issued a $245.00 price target on shares of Becton Dickinson and in a research report on Friday, November 3rd. Four research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. Becton Dickinson and currently has an average rating of “Buy” and an average target price of $237.27.

Becton Dickinson and (NYSE:BDX) opened at $219.95 on Friday. The company has a current ratio of 1.54, a quick ratio of 0.93 and a debt-to-equity ratio of 1.04. Becton Dickinson and has a 1-year low of $175.66 and a 1-year high of $248.39. The firm has a market cap of $50,460.00, a P/E ratio of 167.90, a price-to-earnings-growth ratio of 1.50 and a beta of 1.12.

Becton Dickinson and (NYSE:BDX) last released its earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 EPS for the quarter, topping the consensus estimate of $2.41 by $0.07. Becton Dickinson and had a net margin of 2.71% and a return on equity of 16.19%. The firm had revenue of $3.08 billion for the quarter, compared to the consensus estimate of $3.05 billion. During the same quarter in the previous year, the firm earned $2.33 earnings per share. The company’s quarterly revenue was up 5.4% compared to the same quarter last year. equities research analysts forecast that Becton Dickinson and will post 10.94 EPS for the current fiscal year.

In other Becton Dickinson and news, Director Timothy M. Ring sold 269,661 shares of the business’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $217.82, for a total transaction of $58,737,559.02. Following the transaction, the director now owns 295,753 shares in the company, valued at $64,420,918.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.00% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Family Firm Inc. lifted its stake in Becton Dickinson and by 0.5% in the second quarter. Family Firm Inc. now owns 1,212 shares of the medical instruments supplier’s stock worth $236,000 after acquiring an additional 6 shares during the period. Northwest Quadrant Wealth Management LLC lifted its stake in Becton Dickinson and by 0.4% in the second quarter. Northwest Quadrant Wealth Management LLC now owns 1,686 shares of the medical instruments supplier’s stock worth $332,000 after acquiring an additional 6 shares during the period. NBT Bank N A NY lifted its stake in Becton Dickinson and by 0.3% in the second quarter. NBT Bank N A NY now owns 3,351 shares of the medical instruments supplier’s stock worth $654,000 after acquiring an additional 10 shares during the period. Good Life Advisors LLC lifted its stake in Becton Dickinson and by 0.6% in the second quarter. Good Life Advisors LLC now owns 2,494 shares of the medical instruments supplier’s stock worth $491,000 after acquiring an additional 14 shares during the period. Finally, Pathstone Family Office LLC lifted its stake in Becton Dickinson and by 0.4% in the second quarter. Pathstone Family Office LLC now owns 3,974 shares of the medical instruments supplier’s stock worth $2,530,000 after acquiring an additional 15 shares during the period. Hedge funds and other institutional investors own 75.56% of the company’s stock.

WARNING: “Becton Dickinson and (BDX) Given “Buy” Rating at Bank of America” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/15/becton-dickinson-and-bdx-given-buy-rating-at-bank-of-america.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Analyst Recommendations for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply